Bridgeway Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Bridgeway Capital Management’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-53,900	Closed	-$15K	–	1497
2022 Q3	$15K	Sell	53,900 -16,000	-23%	-$6.33K	﹤0.01%	1397
2022 Q2	$25K	Sell	69,900 -10,000	-13%	-$5.06K	﹤0.01%	1308
2022 Q1	$54K	Sell	79,900 -43,000	-35%	-$47.2K	﹤0.01%	1287
2021 Q4	$284K	Sell	122,900 -53,600	-30%	-$181K	0.01%	1109
2021 Q3	$808K	Buy	176,500 +100,000	+131%	+$440K	0.02%	885
2021 Q2	$340K	Sell	76,500 -106,500	-58%	-$542K	0.01%	1182
2021 Q1	$1.33M	Buy	183,000 +98,600	+117%	+$811K	0.02%	762
2020 Q4	$644K	Hold	84,400	–	–	0.01%	865
2020 Q3	$766K	Sell	84,400 -44,000	-34%	-$334K	0.02%	754
2020 Q2	$1.09M	Buy	128,400 +114,700	+837%	+$755K	0.02%	620
2020 Q1	$68K	Buy	+13,700	New	+$107K	﹤0.01%	1209

Bridgeway Capital Management's LOGC Position: Q4 2022 in Review

Bridgeway Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 53,900 shares — an estimated $15K sold.

Bridgeway Capital Management first reported a position in LOGC in Q1 2020 and held it in 11 quarters. The position peaked at $1.33M in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Bridgeway Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Bridgeway Capital Management sold 53,900 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $15K.
Bridgeway Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Bridgeway Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.33M in Q1 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.